Inj, vanco (tyzavan) 10mg
Products billed under this code include Tyzavan, Vancomycin HCl.
Payment limit per 10 MG, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J3375
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9466-06 | 750 | $107.25 |
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9467-06 | 1050 | $150.15 |
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9468-12 | 900 | $128.70 |
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9469-06 | 900 | $128.70 |
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9470-06 | 1200 | $171.60 |
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9471-12 | 600 | $85.80 |
| Tyzavan | Hikma Pharmaceuticals USA Inc. | 00143-9472-12 | 1200 | $171.60 |
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0041-03 | 600 | $85.80 |
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0042-03 | 1200 | $171.60 |
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0043-02 | 900 | $128.70 |
Show all 14 products
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0044-02 | 1200 | $171.60 |
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0056-03 | 900 | $128.70 |
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0057-02 | 750 | $107.25 |
| Vancomycin HCl | Xellia Pharmaceuticals USA, LLC. | 70594-0058-02 | 1050 | $150.15 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.143 | +$0.001 | 10 MG | Inj, vanco (tyzavan) 10mg | v1, posted September 17, 2026 |
| 3Q26 | $0.142 | −$0.02 | 10 MG | Inj vancomycin (xellia) 10mg | v1, posted September 15, 2026 |
| 2Q26 | $0.162 | +$0.028 | 10 MG | Inj vancomycin (xellia) 10mg | v1, posted September 15, 2026 |
| 1Q26 | $0.134 | −$0.005 | 10 MG | Inj vancomycin (xellia) 10mg | v1, posted September 15, 2026 |
| 4Q25 | $0.139 | +$0.005 | 10 MG | Inj vancomycin (xellia) 10mg | v1, posted September 8, 2026 |
| 3Q25 | $0.134 | – | 10 MG | Inj vancomycin (xellia) 10mg | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026